Ketamine only
Phase 2Small molecule
Ketamine only is one of 23 small molecule programs targeting Long COVID-19. It is currently in Phase 2.
2
Indications
5
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
29 competitors in Long COVID-19
#DrugCompanyPhaseTrials
1Norvir
AbbVieApproved
Corlanor
AmgenApproved
Revia
TevaApproved
Epidiolex
Jazz PharmaceuticalsApproved
Valtrex
GGlaxo Dba Glaxosmithkline
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Trental
VValidus Pharmaceuticals
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Olumiant
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Post Spinal Anesthesia Shivering1 trial
Post Operative Pain1 trial
Low-Dose Ketamine Infusion for Post-Operative Pain in Patients Undergoing Laparoscopic Cholecyctectomy
Completed·—·Phase 1·NCT06966596·116 enrolled
Pediatric1 trial
Ketamine/Propofol vs Ketamine Alone for Pediatric Fracture Reduction
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT00490997·140 enrolled
Pilot Study1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ketamine only. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Pennsylvania